These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37822513)

  • 41. Evidence for Early Cyclosporine Treatment for Hunner Lesion Interstitial Cystitis.
    Vollstedt A; Tennyson L; Turner K; Hasenau D; Saon M; McCartney T; Beck D; Gilleran J; Peters K
    Female Pelvic Med Reconstr Surg; 2022 Jan; 28(1):e1-e5. PubMed ID: 34608034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene expression analysis of urine sediment: evaluation for potential noninvasive markers of interstitial cystitis/bladder pain syndrome.
    Blalock EM; Korrect GS; Stromberg AJ; Erickson DR
    J Urol; 2012 Feb; 187(2):725-32. PubMed ID: 22177197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic efficacy of narrow band imaging-assisted transurethral electrocoagulation for ulcer-type interstitial cystitis/painful bladder syndrome.
    Kajiwara M; Inoue S; Kobayashi K; Ohara S; Teishima J; Matsubara A
    Int J Urol; 2014 Apr; 21 Suppl 1():57-60. PubMed ID: 24807500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome.
    Lim YN; Dwyer P; Murray C; Karmakar D; Rosamilia A; Thomas E
    Int Urogynecol J; 2017 Jul; 28(7):1085-1089. PubMed ID: 27987022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of diagnostic serum biomarkers for Hunner-type interstitial cystitis.
    Torimoto K; Ueda T; Kasahara M; Hirayama A; Matsushita C; Matsumoto Y; Gotoh D; Nakai Y; Miyake M; Aoki K; Fujimoto K
    Low Urin Tract Symptoms; 2022 Sep; 14(5):334-340. PubMed ID: 35307976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical characteristics of self-reported nocturia in patients with interstitial cystitis, and effects of bladder hydrodistention (with fulguration of Hunner lesions) on nocturia.
    Otsuka A; Suzuki T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Miyake H
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O141-O146. PubMed ID: 30010251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [CLINICAL EFFICACY OF DIETARY MANIPULATION AS COMPLEMENTARY AND ALTERNATIVE MEDICINE THERAPIES ON FEMALE INTERSTITIAL CYSTITIS PATIENTS].
    Oh-Oka H
    Nihon Hinyokika Gakkai Zasshi; 2016; 107(3):177-183. PubMed ID: 28740049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of urologic and non-urologic presentation in interstitial cystitis/bladder pain syndrome patients with and without Hunner lesions.
    Van Moh F; Vetter J; Lai HH
    Neurourol Urodyn; 2018 Nov; 37(8):2911-2918. PubMed ID: 30187950
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
    Chartier-Kastler E; Le Normand L; Ruffion A; Dargent F; Braguet R; Saussine C; Tanneau Y; Graziana JP; Ragni E; Rabut B; Rousseau T; Biardeau X; Gamé X; Pierrevelcin J; Brassart E; Fourmarier M; Stoica G; Berrogain N; Yaghi N; Pecoux F; Capon G; Ferchaud J; Peyrat L; Bryckaert PE; Karsenty G; Melotti A; Abouihia A; Keller DUJ; Cornu JN
    Eur Urol Focus; 2021 Nov; 7(6):1430-1437. PubMed ID: 32907782
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial.
    Jiang YH; Jhang JF; Lee CL; Kuo HC
    Neurourol Urodyn; 2018 Apr; 37(4):1467-1473. PubMed ID: 29331031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of low-dose triple therapy using gabapentin, amitriptyline, and a nonsteroidal anti-inflammatory drug for overactive bladder symptoms in patients with bladder pain syndrome.
    Kwon WA; Ahn SH; Oh TH; Lee JW; Han DY; Jeong HJ
    Int Neurourol J; 2013 Jun; 17(2):78-82. PubMed ID: 23869272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment.
    Jhang JF; Yu WR; Kuo HC
    Toxins (Basel); 2023 Feb; 15(2):. PubMed ID: 36828435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Efficacy of electroacupuncture nerve stimulation therapy for interstitial cystitis/bladder pain syndrome].
    Lv TT; Lv JW; Wang SY; Jiang C; Gu YJ; Liu HR
    Zhongguo Zhen Jiu; 2019 May; 39(5):467-72. PubMed ID: 31099215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patterns and predictors of Hunner lesion recurrence in patients with interstitial cystitis.
    Han JY; Shin JH; Choo MS
    Neurourol Urodyn; 2019 Jun; 38(5):1392-1398. PubMed ID: 30945347
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the therapeutic effects of 15 mg and 30 mg initial daily prednisolone doses in patients with subacute thyroiditis: a multicenter, randomized, open-label, parallel-controlled trial.
    Zeng J; Jia A; Zhang J; Gao B; Xu J; Xing Y; Jing X; Jiao Y; Wang J; Xu W; Gao L; Shang L; Xu S
    Ann Med; 2023; 55(2):2288941. PubMed ID: 38048390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment-A prospective clinical trial.
    Jhang JF; Lin TY; Kuo HC
    Neurourol Urodyn; 2019 Feb; 38(2):703-709. PubMed ID: 30576011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Micronized Palmitoylethanolamide-Polydatin Reduces the Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome.
    Cervigni M; Nasta L; Schievano C; Lampropoulou N; Ostardo E
    Biomed Res Int; 2019; 2019():9828397. PubMed ID: 31828153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interstitial cystitis, bladder pain syndrome, hypersensitive bladder, and interstitial cystitis/bladder pain syndrome - clarification of definitions and relationships.
    Homma Y
    Int J Urol; 2019 Jun; 26 Suppl 1():20-24. PubMed ID: 31144731
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fulguration for Hunner ulcers: long-term clinical outcomes.
    Hillelsohn JH; Rais-Bahrami S; Friedlander JI; Okhunov Z; Kashan M; Rosen L; Moldwin RM
    J Urol; 2012 Dec; 188(6):2238-41. PubMed ID: 23083651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis?
    Gamper M; Regauer S; Welter J; Eberhard J; Viereck V
    J Urol; 2015 Jun; 193(6):1994-2000. PubMed ID: 25596361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.